A Study To Evaluate The Treatment Pattern Of Moderate-to-Severe Asthma Patients In China - PRESENT

Study identifier:D2287R00198

ClinicalTrials.gov identifier:NCT06422663

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

A Prospective, Observational, Multicentre Study To Evaluate The Treatment Pattern Of Moderate-to-Severe Asthma Patients In China

Medical condition

Moderate-to-Severe Asthma

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

500

Study type

Observational

Age

12 Years - 130 Years

Date

Study Start Date: 22 Mar 2024
Estimated Primary Completion Date: 28 Feb 2025
Estimated Study Completion Date: 28 Feb 2025

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria